vs
Side-by-side financial comparison of HUTCHMED (China) Ltd (HCM) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
HUTCHMED (China) Ltd is the larger business by last-quarter revenue ($270.8M vs $151.7M, roughly 1.8× Nutex Health, Inc.). Nutex Health, Inc. runs the higher net margin — 7.8% vs 0.7%, a 7.1% gap on every dollar of revenue. On growth, HUTCHMED (China) Ltd posted the faster year-over-year revenue change (-16.5% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $3.4M).
HUTCHMED (China) LtdHCMEarnings & Financial Report
HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
HCM vs NUTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.8M | $151.7M |
| Net Profit | $2.0M | $11.8M |
| Gross Margin | 37.7% | 30.4% |
| Operating Margin | -13.2% | 20.4% |
| Net Margin | 0.7% | 7.8% |
| Revenue YoY | -16.5% | -41.1% |
| Net Profit YoY | -83.6% | -80.8% |
| EPS (diluted) | $0.00 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.8M | $151.7M | ||
| Q3 25 | — | $267.8M | ||
| Q2 25 | $277.7M | $244.0M | ||
| Q1 25 | $324.5M | $211.8M | ||
| Q4 24 | — | $257.6M | ||
| Q3 24 | — | $78.8M | ||
| Q2 24 | $305.7M | $76.1M | ||
| Q1 24 | — | $67.5M |
| Q4 25 | $2.0M | $11.8M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | $455.0M | $-17.7M | ||
| Q1 25 | $11.9M | $21.2M | ||
| Q4 24 | — | $61.6M | ||
| Q3 24 | — | $-8.8M | ||
| Q2 24 | $25.8M | $-364.0K | ||
| Q1 24 | — | $-364.0K |
| Q4 25 | 37.7% | 30.4% | ||
| Q3 25 | — | 57.8% | ||
| Q2 25 | 0.1% | 51.2% | ||
| Q1 25 | 48.0% | 55.9% | ||
| Q4 24 | — | 55.0% | ||
| Q3 24 | — | 27.8% | ||
| Q2 24 | 41.1% | 29.7% | ||
| Q1 24 | — | 15.1% |
| Q4 25 | -13.2% | 20.4% | ||
| Q3 25 | — | 48.7% | ||
| Q2 25 | -1.3% | 13.8% | ||
| Q1 25 | -5.0% | 38.1% | ||
| Q4 24 | — | 44.4% | ||
| Q3 24 | — | 12.3% | ||
| Q2 24 | -9.0% | 7.0% | ||
| Q1 24 | — | 2.1% |
| Q4 25 | 0.7% | 7.8% | ||
| Q3 25 | — | 20.7% | ||
| Q2 25 | 163.8% | -7.3% | ||
| Q1 25 | 3.7% | 10.0% | ||
| Q4 24 | — | 23.9% | ||
| Q3 24 | — | -11.2% | ||
| Q2 24 | 8.4% | -0.5% | ||
| Q1 24 | — | -0.5% |
| Q4 25 | $0.00 | $2.34 | ||
| Q3 25 | — | $7.76 | ||
| Q2 25 | $0.52 | $-2.95 | ||
| Q1 25 | $0.01 | $3.33 | ||
| Q4 24 | — | $11.56 | ||
| Q3 24 | — | $-1.72 | ||
| Q2 24 | $0.03 | $-0.07 | ||
| Q1 24 | — | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $185.6M |
| Total DebtLower is stronger | $93.2M | — |
| Stockholders' EquityBook value | $1.2B | $329.4M |
| Total Assets | $1.8B | $918.5M |
| Debt / EquityLower = less leverage | 0.08× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $185.6M | ||
| Q3 25 | — | $166.0M | ||
| Q2 25 | $1.4B | $96.7M | ||
| Q1 25 | $836.1M | $84.7M | ||
| Q4 24 | — | $40.6M | ||
| Q3 24 | — | $46.9M | ||
| Q2 24 | $802.5M | $40.8M | ||
| Q1 24 | — | $30.0M |
| Q4 25 | $93.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $93.4M | — | ||
| Q1 25 | $82.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $82.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $329.4M | ||
| Q3 25 | — | $317.2M | ||
| Q2 25 | $1.2B | $235.3M | ||
| Q1 25 | $759.9M | $176.9M | ||
| Q4 24 | — | $132.4M | ||
| Q3 24 | — | $60.4M | ||
| Q2 24 | $740.1M | $62.7M | ||
| Q1 24 | — | $63.0M |
| Q4 25 | $1.8B | $918.5M | ||
| Q3 25 | — | $964.5M | ||
| Q2 25 | $1.8B | $841.0M | ||
| Q1 25 | $1.3B | $761.9M | ||
| Q4 24 | — | $655.3M | ||
| Q3 24 | — | $438.5M | ||
| Q2 24 | $1.3B | $422.4M | ||
| Q1 24 | — | $404.3M |
| Q4 25 | 0.08× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.08× | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.2M | $70.4M |
| Free Cash FlowOCF − Capex | $3.4M | $69.0M |
| FCF MarginFCF / Revenue | 1.2% | 45.5% |
| Capex IntensityCapex / Revenue | 1.8% | 0.9% |
| Cash ConversionOCF / Net Profit | 4.21× | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | $-96.2M | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.2M | $70.4M | ||
| Q3 25 | — | $99.5M | ||
| Q2 25 | $-72.9M | $27.3M | ||
| Q1 25 | $40.3M | $51.0M | ||
| Q4 24 | — | $54.0K | ||
| Q3 24 | — | $6.8M | ||
| Q2 24 | $-39.8M | $13.3M | ||
| Q1 24 | — | $3.1M |
| Q4 25 | $3.4M | $69.0M | ||
| Q3 25 | — | $99.2M | ||
| Q2 25 | $-82.2M | $26.5M | ||
| Q1 25 | $32.5M | $50.9M | ||
| Q4 24 | — | $-341.0K | ||
| Q3 24 | — | $6.2M | ||
| Q2 24 | $-49.9M | $12.7M | ||
| Q1 24 | — | $2.3M |
| Q4 25 | 1.2% | 45.5% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | -29.6% | 10.9% | ||
| Q1 25 | 10.0% | 24.0% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | -16.3% | 16.7% | ||
| Q1 24 | — | 3.4% |
| Q4 25 | 1.8% | 0.9% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | 3.3% | 0.3% | ||
| Q1 25 | 2.4% | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | 4.21× | 5.95× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | 3.38× | 2.40× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.54× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCM
Segment breakdown not available.
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
